At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MATCH Treatment Subprotocol E: Osimertinib (AZD9291) in Patients With Tumors Having EGFR T790M Mutations or Rare Activating Mutations of EGFR
In Brief
A Phase 2 clinical trial evaluating Biopsy Procedure, Biospecimen Collection, and 4 other interventions for Advanced Lymphoma and 5 related conditions. Active but no longer recruiting, targeting 19 participants across 1 site.
Detailed Summary
This phase II MATCH treatment trial evaluates the effectiveness of osimertinib (AZD9291) in treating patients with cancer that has certain genetic changes called EGFR mutations. Osimertinib is in a class of medications called kinase inhibitors. It works by blocking the action of mutant forms of the EGFR protein, which play a key role in tumor cell growth. Osimertinib may cause tumor cell death and inhibit tumor growth in EGFR-overexpressing tumor cells, thereby stopping or slowing the spread of tumor cells.
Study Details
Timeline
Interventions
Undergo biopsy
Undergo blood sample collection
Undergo ECHO
Undergo MUGA
Given PO
Undergo radiologic evaluation